Lisdexamfetamine and binge-eating disorder: A systematic review and meta-analysis of the preclinical and clinical data with a focus on mechanism of drug action in treating the disorder

•LDX is the only approved drug to treat Binge Eating Disorder.•The neuropsychopharmacological mechanisms underlying treatment efficacy remain unclear.•LDX reduces homeostatic and hedonic food intake in rodents and humans.•LDX likely improves BED through catecholaminergic and serotoninergic actions on appetite/satiety, reward, and cognitive processes.